ATE449078T1 - 5-ht7 rezeptor-antagonisten - Google Patents
5-ht7 rezeptor-antagonistenInfo
- Publication number
- ATE449078T1 ATE449078T1 AT01928857T AT01928857T ATE449078T1 AT E449078 T1 ATE449078 T1 AT E449078T1 AT 01928857 T AT01928857 T AT 01928857T AT 01928857 T AT01928857 T AT 01928857T AT E449078 T1 ATE449078 T1 AT E449078T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- receptor antagonists
- amino
- schizophrenia
- anxiety
- Prior art date
Links
- 108091005436 5-HT7 receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- QQOWHRYOXYEMTL-UHFFFAOYSA-N triazin-4-amine Chemical class N=C1C=CN=NN1 QQOWHRYOXYEMTL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20293100P | 2000-05-09 | 2000-05-09 | |
| PCT/US2001/013324 WO2001085701A1 (en) | 2000-05-09 | 2001-04-25 | 5-ht7 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE449078T1 true ATE449078T1 (de) | 2009-12-15 |
Family
ID=22751788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01928857T ATE449078T1 (de) | 2000-05-09 | 2001-04-25 | 5-ht7 rezeptor-antagonisten |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6630469B2 (de) |
| EP (1) | EP1280781B1 (de) |
| JP (1) | JP2003532714A (de) |
| AT (1) | ATE449078T1 (de) |
| AU (1) | AU2001255669A1 (de) |
| CA (1) | CA2409729A1 (de) |
| DE (1) | DE60140530D1 (de) |
| ES (1) | ES2334491T3 (de) |
| WO (1) | WO2001085701A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375222B2 (en) * | 2002-02-05 | 2008-05-20 | Astellas Pharma Inc. | 2,4,6-Triamino-1,3,5-triazine derivative |
| EP1727806A1 (de) * | 2004-01-16 | 2006-12-06 | Novartis AG | 2,4-diaminopyrimidine und deren verwendung bei der induktion von kardiomyogenese |
| WO2007025144A1 (en) * | 2005-08-24 | 2007-03-01 | University Of Illinois - Chicago | 5-ht2c receptor agonists as anorectic agents |
| AP2009005010A0 (en) | 2007-04-18 | 2009-10-31 | Pfizer Prod Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
| JP5810099B2 (ja) | 2010-02-04 | 2015-11-11 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | ５−ｈｔ（２ｂ）受容体でアンタゴニスト活性を有する高選択性５−ｈｔ（２ｃ）受容体アゴニスト |
| JP2013531801A (ja) * | 2010-07-02 | 2013-08-08 | ヴェンタナ メディカル システムズ， インク． | 標的検出のためのハプテンコンジュゲート |
| CN102389744B (zh) * | 2011-09-09 | 2013-08-21 | 大连理工大学 | 一类均三嗪两性甜菜碱表面活性剂及其合成方法 |
| RU2015106915A (ru) * | 2012-08-01 | 2016-09-20 | Мерк Шарп И Доум Корп. | МОДУЛЯТОРЫ α7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ИХ ПРИМЕНЕНИЕ |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2016123164A1 (en) | 2015-01-29 | 2016-08-04 | The Board Of Trustees Of The University Of Illinois | Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists |
| GEAP202014908A (en) | 2016-03-22 | 2020-03-10 | Merck Sharp & Dohme | Allosteric modulators of nicotinic acetylcholine receptors |
| EP4725942A1 (de) * | 2024-10-09 | 2026-04-15 | Sibylla Biotech S.p.A. | Verbindungen mit wirkung auf den cyclin-d1-pfad und ihre verwendung |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1288903A (de) | 1971-04-16 | 1972-09-13 | ||
| BE792914A (fr) | 1971-12-18 | 1973-06-18 | Schering Ag | Derives amino de n-heterocycles et leur procede de preparation |
| US3816629A (en) | 1972-09-01 | 1974-06-11 | Kyorin Seiyaku Kk | 2-amino-4,6-diphenethylamino-s-triazine for treating arteriosclerosis |
| DE3717480A1 (de) | 1987-05-23 | 1988-12-01 | Shell Agrar Gmbh & Co Kg | Neue herbizid und mikrobizid wirksame 2,6-diaminopyrimidine |
| BR9205906A (pt) | 1991-04-17 | 1994-07-05 | Pfizer | Derivados de pirimidina para aumento da atividade antitumoral |
| US5491234A (en) | 1992-03-30 | 1996-02-13 | Pfizer Inc. | Pyrimidine derivatives for enhancing antitumor activity |
| DE19531084A1 (de) * | 1995-08-24 | 1997-02-27 | Hoechst Schering Agrevo Gmbh | 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| US6117996A (en) | 1995-09-20 | 2000-09-12 | Novo Nordisk A/S | Triazine based ligands and use thereof |
| JP3967783B2 (ja) | 1996-07-31 | 2007-08-29 | 富士フイルム株式会社 | 顔料分散組成物及びそれを用いた着色感光性組成物 |
| DE19641694A1 (de) | 1996-10-10 | 1998-04-16 | Bayer Ag | Substituierte 2,4-Diamino-1,3,5-triazine |
| DE19704922A1 (de) | 1997-02-10 | 1998-08-13 | Hoechst Schering Agrevo Gmbh | 2,4-Diamino-1,3,5-triazine, ihre Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| BR9910590A (pt) | 1998-05-19 | 2001-01-23 | Alcon Lab Inc | Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada |
-
2001
- 2001-04-24 US US09/841,273 patent/US6630469B2/en not_active Expired - Lifetime
- 2001-04-25 ES ES01928857T patent/ES2334491T3/es not_active Expired - Lifetime
- 2001-04-25 WO PCT/US2001/013324 patent/WO2001085701A1/en not_active Ceased
- 2001-04-25 AT AT01928857T patent/ATE449078T1/de not_active IP Right Cessation
- 2001-04-25 EP EP01928857A patent/EP1280781B1/de not_active Expired - Lifetime
- 2001-04-25 DE DE60140530T patent/DE60140530D1/de not_active Expired - Lifetime
- 2001-04-25 JP JP2001582302A patent/JP2003532714A/ja active Pending
- 2001-04-25 CA CA002409729A patent/CA2409729A1/en not_active Abandoned
- 2001-04-25 AU AU2001255669A patent/AU2001255669A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60140530D1 (de) | 2009-12-31 |
| CA2409729A1 (en) | 2001-11-15 |
| WO2001085701A1 (en) | 2001-11-15 |
| AU2001255669A1 (en) | 2001-11-20 |
| EP1280781A4 (de) | 2003-08-06 |
| EP1280781B1 (de) | 2009-11-18 |
| EP1280781A1 (de) | 2003-02-05 |
| US20020032199A1 (en) | 2002-03-14 |
| ES2334491T3 (es) | 2010-03-11 |
| US6630469B2 (en) | 2003-10-07 |
| JP2003532714A (ja) | 2003-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60215000D1 (de) | DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN | |
| NO20014303D0 (no) | JAK-3-inhibitorer for behandling av allergiske lidelser | |
| DE60140530D1 (de) | 5-ht7 rezeptor-antagonisten | |
| ATE479686T1 (de) | Pyridopyrrolizin- und pyridoindolizinderivate | |
| DE60218458D1 (de) | Isochinolinon derivate als parp inhibitoren | |
| BRPI0418112A (pt) | inibidores de p-38 quinase bicìclico heterocìclicos | |
| ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
| DE60234116D1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems | |
| ATE447561T1 (de) | Substituierte aryl 1,4-pyrazin derivate | |
| PT1349839E (pt) | Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato | |
| CY1106165T1 (el) | Παραγωγα ινδολινονης για την τροποποιηση της c-kit πρωτεϊνικης τυροσινικης κινασης | |
| DK1196397T3 (da) | Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet | |
| DK1578740T3 (da) | 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet | |
| DE60203797D1 (de) | Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten | |
| ATE259230T1 (de) | Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres | |
| NO994850L (no) | Farmakologiske midler | |
| EA200200742A1 (ru) | 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии | |
| ATE286883T1 (de) | Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität | |
| TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
| DE60114027D1 (de) | Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion | |
| DE60221275D1 (de) | Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma | |
| DK1000046T3 (da) | Piperazinderivater, der er aktive på den nedre urinvejskanal | |
| ATE292107T1 (de) | Verwendung von carbonylaminoderivaten gegen zentralnervensystem-störungen | |
| EA200601592A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
| ATE330599T1 (de) | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |